|
1
|
Skálová A, Vanecek T, Sima R, Laco J,
Weinreb I, Perez-Ordonez B, Starek I, Geierova M, Simpson RH,
Passador-Santos F, et al: Mammary analogue secretory carcinoma of
salivary glands, containing the ETV6-NTRK3 fusion gene: A hitherto
undescribed salivary gland tumor entity. Am J Surg Pathol.
34:599–608. 2010.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Seethala RR and Stenman G: Update from the
4th edition of the world health organization classification of head
and neck tumours: Tumors of the salivary gland. Head Neck Pathol.
11:55–67. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Baněčková M, Thompson LDR, Hyrcza MD,
Vaněček T, Agaimy A, Laco J, Simpson RHW, Di Palma S, Stevens TM,
Brcic L, et al: Salivary gland secretory carcinoma:
clinicopathologic and genetic characteristics of 215 cases and
proposal for a grading system. Am J Surg Pathol. 47:661–677.
2023.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Majewska H, Skálová A, Stodulski D,
Klimková A, Steiner P, Stankiewicz C and Biernat W: Mammary
analogue secretory carcinoma of salivary glands: A new entity
associated with ETV6 gene rearrangement. Virchows Arch.
466:245–254. 2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
American Joint Committee on Cancer: Major
Salivary Glands. In: AJCC Cancer Staging Manual. 8th edition.
Springer, New York, NY, 2017.
|
|
6
|
Parikh AS, Khawaja A, Puram SV, Srikanth
P, Tjoa T, Lee H, Sethi RKV, Bulbul M, Varvares MA, Rocco JW, et
al: Outcomes and prognostic factors in parotid gland malignancies:
A 10-year single center experience. Laryngoscope Investig
Otolaryngol. 4:632–639. 2019.PubMed/NCBI View
Article : Google Scholar
|
|
7
|
Yosefof E, Boldes T, Dan D, Robenshtok E,
Strenov Y, Bachar G, Shpitzer T and Mizrachi A: Salivary gland
secretory carcinoma; Review of 13 years world-wide experience and
meta-analysis. Laryngoscope. 134:1716–1724. 2024.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Wang S, Peng Y, Jiang C, Lin Z,
Infante-Cossio P and Li J: Case series of secretory carcinoma in
the parotid glands. Gland Surg. 13:2198–2205. 2024.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kashiwagi N, Nakatsuka SI, Murakami T,
Enoki E, Yamamoto K, Nakanishi K, Chikugo T, Kurisu Y, Kimura M,
Hyodo T, et al: MR imaging features of mammary analogue secretory
carcinoma and acinic cell carcinoma of the salivary gland: A
preliminary report. Dentomaxillofac Radiol.
47(20170218)2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Han F, Liu F, Wang H, Qin Y, Lu Q, Wu X,
Guo Z and Nan X: Clinicopathologic characterization of secretory
carcinoma of salivary gland. World J Surg Oncol.
22(282)2024.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kala PS, Gupta M and Thapliyal N: Efficacy
of fine-needle aspiration cytology in diagnosing secretory
carcinoma of salivary gland: A systematic review and meta-analysis.
Acta Cytol. 68:83–106. 2024.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Wiles AB, Gabrielson M, Baloch ZW, Faquin
WC, Jo VY, Callegari F, Kholova I, Song S, Centeno BA, Ali SZ, et
al: Secretory carcinoma of the salivary gland, a rare entity: An
international multi-institutional study. Cancer Cytopathol.
130:684–694. 2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Stow N, Veivers D and Poole A: Fine-needle
aspiration cytology in the management of salivary gland tumors: An
Australian experience. Ear Nose Throat J. 83:128–131.
2004.PubMed/NCBI
|
|
14
|
Skálová A, Gnepp DR, Lewis JS Jr, Hunt JL,
Bishop JA, Hellquist H, Rinaldo A, Vander Poorten V and Ferlito A:
Newly described entities in salivary gland pathology. Am J Surg
Pathol. 41:e33–e47. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Khurram SA and Speight PM:
Characterisation of DOG-1 expression in salivary gland tumours and
comparison with myoepithelial markers. Head Neck Pathol.
13:140–148. 2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Skálová A, Vanecek T, Simpson RH, Laco J,
Majewska H, Baneckova M, Steiner P and Michal M: Mammary analogue
secretory carcinoma of salivary glands: Molecular analysis of 25
ETV6 gene rearranged tumors with lack of detection of classical
ETV6-NTRK3 fusion transcript by standard RT-PCR: Report of 4 cases
harboring ETV6-X gene fusion. Am J Surg Pathol. 40:3–13.
2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Yamamoto H, Nozaki Y, Sugii A, Taguchi K,
Hongo T, Jiromaru R, Sato M, Nakano T, Hashimoto K, Fujiwara M and
Oda Y: Pan-tropomyosin receptor kinase immunoreactivity, ETV6-NTRK3
fusion subtypes, and RET rearrangement in salivary secretory
carcinoma. Hum Pathol. 109:37–44. 2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Solomon JP, Benayed R, Hechtman JF and
Ladanyi M: Identifying patients with NTRK fusion cancer. Ann Oncol.
30 (Suppl 8):viii16–viii22. 2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Ishihara A, Kuwabara H, Yasuda E, Jinnin
T, Higashino M, Nagao T, Haginomori SI and Hirose Y: Salivary gland
secretory carcinoma with an ETV6::RET fusion: A case report. Biomed
Rep. 22(73)2025.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Rooper LM, Karantanos T, Ning Y, Bishop
JA, Gordon SW and Kang H: Salivary secretory carcinoma with a novel
ETV6-MET fusion: Expanding the molecular spectrum of a recently
described entity. Am J Surg Pathol. 42:1121–1126. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Guilmette J, Dias-Santagata D, Nosé V,
Lennerz JK and Sadow PM: Novel gene fusions in secretory carcinoma
of the salivary glands: enlarging the ETV6 family. Hum Pathol.
83:50–58. 2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
NCCN Clinical Practice Guidelines in
Oncology: Head and Neck Cancers (Version 1.2026). Available from:
https://www.nccn.org/guidelines/.
|
|
23
|
Yassin-Kassab A, Gainor D and Sufyan AS:
Atypical presentation of mammary analogue secretory carcinoma of
the lip. Ear Nose Throat J. 101:NP212–NP217. 2022.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Al-Mamgani A, van Rooij P, Verduijn GM,
Meeuwis CA and Levendag PC: Long-term outcomes and quality of life
of 186 patients with primary parotid carcinoma treated with surgery
and radiotherapy at the Daniel den Hoed Cancer Center. Int J Radiat
Oncol Biol Phys. 84:189–195. 2012.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Cipriani NA, Blair EA, Finkle J, Kraninger
JL, Straus CM, Villaflor VM and Ginat DT: Salivary gland secretory
carcinoma with high-grade transformation, CDKN2A/B loss, distant
metastasis, and lack of sustained response to crizotinib. Int J
Surg Pathol. 25:613–618. 2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Xu B, Viswanathan K, Umrau K, Al-Ameri
TAD, Dogan S, Magliocca K, Ghossein RA, Cipriani NA and Katabi N:
Secretory carcinoma of the salivary gland: A multi-institutional
clinicopathologic study of 90 cases with emphasis on grading and
prognostic factors. Histopathology. 81:670–679. 2022.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Doebele RC, Drilon A, Paz-Ares L, Siena S,
Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, et al:
Entrectinib in patients with advanced or metastatic NTRK
fusion-positive solid tumours: Integrated analysis of three phase
1-2 trials. Lancet Oncol. 21:271–282. 2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Drilon A, Laetsch TW, Kummar S, DuBois SG,
Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo
AS, et al: Efficacy of larotrectinib in TRK fusion-positive cancers
in adults and children. N Engl J Med. 378:731–739. 2018.PubMed/NCBI View Article : Google Scholar
|
